What’s next for MPN?

Ruben Mesa, MD, from the Mayo Clinic, Scottsdale, AZ, USA discusses current developments in myeloproliferative neoplasms (MPNs) at the 2016 Annual Meeting of the British Society of Haematology (BSH) and International Society of Hematology (ISH) held in Glasgow, Scotland. According to Dr Mesa, it is a very exciting time for MPNs as new JAK inhibitors such as pacritinib and NS-018, anti-fibrosing agents such as PRM-151 as well as telomerase inhibitors such as imetelstat, are being developed.

Share this video  
18th April 2016